RE:RE:A much better Offer will comeThank you for the further insights on potential value of the tax loss credits/asset. And, regarding Knight Therapeutics...GUD could be good! And, soon to be better... MONTREAL, CANADA--(Marketwired - Aug 17, 2016) - Knight Therapeutics Inc. (GUD.TO) ("Knight"), a leading Canadian specialty pharmaceutical company, today announced that Samira Sakhia, former CFO of Paladin Labs Inc. ("Paladin"), will be joining the Knight team as President and member of the Board of Directors. In her new role, beginning on August 31, 2016, Samira will report to Jonathan Ross Goodman, CEO of Knight..... During her employment with Paladin, Ms. Sakhia was instrumental in executing in-licensing and acquisition transactions of Canadian and international pharmaceutical products and businesses. In addition, Ms. Sakhia led several M&A and strategic lending transactions as well as equity rounds on the TSX and completed the sale of Paladin to Endo International for over $3 billion. https://finance.yahoo.com/news/knight-reborn-120000265.html Also, note one of their late stage pipeline products - PHOTOFRIN3 Oesophageal cancer, endobronchial cancer, High-grade dysplasia in Barrett's oesophagus, papillary bladder cancer